Navigating the landscape of precios cjc 1295 dac requires evaluating chemical purity, analytical validation, and manufacturing protocols rather than base unit cost alone. This technical overview examines the structural mechanics of CJC-1295 with Drug Affinity Complex (DAC), preclinical literature regarding sustained GH/IGF-1 axis activation, and the critical analytical benchmarks researchers must verify prior to procurement.
Navigating the landscape of precios cjc 1295 dac requires evaluating chemical purity, analytical validation, and manufacturing protocols rather than base unit cost alone. This technical overview examines the structural mechanics of CJC-1295 with Drug Affinity Complex (DAC), preclinical literature regarding sustained GH/IGF-1 axis activation, and the critical analytical benchmarks researchers must verify prior to procurement.
When evaluating precios cjc 1295 dac for analytical or preclinical applications, laboratory buyers must look beyond initial list rates to assess true compound value. The total procurement valuation of CJC-1295 DAC is governed by synthesis method, mass spectrometry identity confirmation, High-Performance Liquid Chromatography (RP-HPLC) purity analysis, and rigorous endotoxin quantification. Substandard preparations lacking independent verification often exhibit variable peptide content, truncated sequence contaminants, or residual counter-ions that destabilize in vitro assays.
In institutional research environments, purchasing decisions depend on reproducible lot-to-lot consistency. High-grade CJC-1295 DAC synthesized in ISO 17025-accredited, GMP-compliant facilities incurs higher quality-assurance overhead, but eliminates batch variance that compromises experimental data. Researchers reviewing options should prioritize verified high-purity compounds over unvalidated low-cost alternatives.
CJC-1295 DAC is a synthetic 29-amino-acid peptide analog of human Growth Hormone-Releasing Hormone (GHRH 1-29) modified at several key residues to enhance enzymatic stability. The native sequence undergoes D-alanine substitution at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These specific structural adjustments protect the peptide backbone against rapid cleavage by dipeptidyl peptidase-IV (DPP-IV), an enzyme responsible for degrading endogenous GHRH within minutes of release.
The defining feature of CJC-1295 DAC is the covalent addition of a maleimidopropionic acid linker attached to the C-terminal lysine residue. This Drug Affinity Complex (DAC) moiety selectively binds to free cysteine-34 residues on circulating serum albumin via a stable thioether bond. By utilizing endogenous albumin as a carrier protein, the effective molecular mass of the complex increases significantly, inhibiting renal clearance and extending the terminal half-life in animal models from minutes to several days.
As a potent agonist of the pituitary growth hormone-releasing hormone receptor (GHRHR), CJC-1295 DAC stimulates signal transduction via the G-protein coupled receptor pathways. Upon receptor activation, intracellular cyclic adenosine monophosphate (cAMP) levels elevate, triggering protein kinase A (PKA) signaling cascades. In rodent and non-human primate models, this cascade prompts the transcription and release of endogenous growth hormone (GH) from somatotropic cells.
Unlike native GHRH, which produces transient secretory spikes, the prolonged circulatory presence of CJC-1295 DAC leads to sustained, pulsatile baseline elevations in both GH and downstream insulin-like growth factor 1 (IGF-1). Preclinical studies indicate that this persistent receptor stimulation maintains physiological pulsatility while expanding total area-under-the-curve (AUC) exposure. This mechanism makes the compound a central subject in tissue repair, metabolic flux, and body composition models.
In vitro data and animal studies demonstrate that CJC-1295 DAC induces dose-dependent increases in plasma GH levels for extended durations following single-dose administration. In preclinical rodent models, a single administration of CJC-1295 DAC sustained elevated IGF-1 concentrations for up to 7 to 10 days. This extended activity profile contrasts sharply with unmodified GHRH analogs, which require multiple daily applications to achieve equivalent systemic exposure.
Research exploring tissue repair mechanisms often leverages CJC-1295 DAC to examine cellular proliferation, collagen synthesis, and extracellular matrix remodeling. Investigators studying skeletal muscle hypertrophy and tendon healing frequently evaluate CJC-1295 DAC alongside other cellular signaling peptides, such as BPC-157 tissue repair models, to monitor synergistic pathways involved in fibroblast activation and microvascular regeneration.
When designing preclinical protocols, researchers must select the appropriate secretagogue based on pharmacokinetic parameters and receptor target specificity. Comparing CJC-1295 DAC against non-conjugated counterparts and ghrelin receptor agonists highlights distinct operational profiles:
While CJC-1295 DAC relies on covalent albumin conjugation for multi-day persistence, CJC-1295 No DAC overview (also known as Mod GRF 1-29) exhibits a short elimination half-life of approximately 30 minutes, making it suitable for acute, transient stimulation protocols. Conversely, selective ghrelin receptor agonists like Ipamorelin target the growth hormone secretagogue receptor (GHSR-1a) rather than GHRHR, offering a distinct mechanism that avoids cortisol or prolactin activation. Short-chain GHRH analogs like Sermorelin represent the truncated 29-amino-acid native sequence without non-natural amino acid substitutions, requiring frequent dosing in animal models due to rapid enzymatic degradation. Understanding these structural differences clarifies why institutional researchers often combine GHRH analogs with GHSR agonists to study complementary secretagogue activity.
The analytical integrity of CJC-1295 DAC directly impacts experimental reproducibility. High-purity peptides intended for laboratory research must undergo rigorous analytical verification using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) coupled with Mass Spectrometry (MS). RP-HPLC quantifies the relative abundance of the target peptide sequence against synthesis impurities, ensuring purity levels exceeding 99.0%.
Mass spectrometry confirms the precise molecular weight of the peptide-DAC conjugate (C152H252N44O42, theoretical MW: ~3647.2 Da), verifying that the maleimide linker remains intact and functional. Furthermore, bacterial endotoxin testing via Limulus Amebocyte Lysate (LAL) assays is critical for cell culture and preclinical models, with strict target thresholds set below 0.5 EU/mg to prevent inflammatory artifact signaling. Evaluating these analytical metrics provides full transparency when assessing suppliers and understanding standard precios cjc 1295 dac.
Proper handling and reconstitution protocols preserve peptide stability and prevent physical aggregation. Reconstitution should be performed under aseptic conditions within a laminar flow hood using sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile endotoxin-free water depending on downstream assay requirements.
To reconstitute lyophilized CJC-1295 DAC: gentle diluent introduction along the inner glass wall of the vial prevents shear force damage to the peptide matrix. The vial should be gently swirled rather than vortexed until completely dissolved. For micro-volume work or automated liquid handling, consult our comprehensive reconstitution guide for concentration calculations, solvent compatibility data, and volumetric conversion charts.
Lyophilized CJC-1295 DAC matrix exhibits high thermodynamic stability when stored under moisture-free conditions. Unopened vials stored at -20°C remain stable for up to 24 months, while long-term storage at -80°C protects against peptide degradation over extended timelines. Desiccant packs should be included in storage containers to prevent moisture absorption during cycle thawing.
Once reconstituted into aqueous solution, peptide stability decreases over time. Reconstituted CJC-1295 DAC maintained at 2°C to 8°C should be used within 21 to 28 days to minimize hydrolytic cleavage. Repeated freeze-thaw cycles must be avoided, as phase changes cause mechanical stress that can cleave the DAC linker or alter tertiary structure. Aliquoting reconstituted stock into single-use micro-centrifuge tubes prior to freezing extends usability for long-term experimental series.
PX1 Research serves academic institutions, contract research organizations (CROs), and private biotechnology laboratories requiring fully verified, USA-manufactured research peptides. Every batch of CJC-1295 DAC supplied by PX1 Research undergoes independent third-party laboratory verification, with lot-specific Certificates of Analysis (COAs) accessible directly through our platform.
For high-throughput research programs requiring bulk quantities or recurring batch allocations, explore our wholesale research procurement services. Institutional accounts receive dedicated supply chain support, consistent lot reservation, and full access to our complete high-purity catalog of analytical-grade compounds shipped directly from our ISO-compliant California and Arizona facilities.
What primary factors determine precios cjc 1295 dac in research procurement?
Pricing is determined by chemical purity standards (e.g., >99% via RP-HPLC), mass spectrometry validation, endotoxin assay testing (<0.5 EU/mg), synthetic complexity of the DAC conjugate, and compliance with US-based manufacturing protocols.
What is the primary operational difference between CJC-1295 DAC and CJC-1295 No DAC?
CJC-1295 DAC contains a maleimidopropionic acid linker that covalently binds serum albumin, extending its biological half-life to several days in animal models. CJC-1295 No DAC lacks this linker and exhibits a short half-life of approximately 30 minutes.
How should CJC-1295 DAC be reconstituted for in vitro laboratory assays?
Reconstitute using sterile Bacteriostatic Water or sterile endotoxin-free diluent by directing the liquid down the inner vial wall. Swirl gently without vortexing to avoid mechanical shear stress on the peptide structure.
What purity metrics are verified on a PX1 Research Certificate of Analysis?
Every lot COA verifies peptide purity via RP-HPLC, correct molecular mass via Mass Spectrometry, residual solvent presence, and endotoxin levels via LAL testing to ensure strict research-grade compliance.
What receptor system does CJC-1295 DAC target in preclinical models?
CJC-1295 DAC acts as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR) in pituitary somatotropes, activating intracellular cAMP/PKA signaling pathways.
What are the recommended storage parameters for unopened CJC-1295 DAC?
Unopened lyophilized vials should be stored at -20°C for up to 24 months or -80°C for long-term preservation. Store away from moisture and light exposure.
Can CJC-1295 DAC be co-administered with GHSR agonists in research models?
In preclinical study designs, GHRH analogs like CJC-1295 DAC are frequently paired with ghrelin receptor agonists like Ipamorelin to investigate complementary signaling pathways governing somatotrope GH release.
Is CJC-1295 DAC suitable for human use or clinical applications?
No. CJC-1295 DAC is strictly manufactured and designated for laboratory research use only. It is not intended for human or animal clinical, diagnostic, therapeutic, or medical application.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.